Truist raises ArriVent BioPharma stock price target on drug data

Guggenheim kept a Buy rating on ArriVent BioPharma (AVBP) with a $30 price target, suggesting a 95.3% upside from the Oct 26 close. The firm cited promising early Phase 1 data for ARR-217 in metastatic colorectal cancer, raising its probability of success to 45%. Recent analyst price targets for AVBP range from $18 to $29.

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.

ArriVent BioPharma reported Phase 1 data for ARR-217, showing a 44.8% response rate at 6 mg/kg in pretreated colorectal cancer patients. The disease control rate was 93.1% at this dose. At 4 mg/kg and higher, the response rate was 34.2% with a 91.8% disease control rate. Grade 3 or higher adverse events occurred in 30.1% of patients. The company plans to advance to Phase 1b dose optimization.

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 · 44.8% ORR at 6mg/kg dose in late-line CRC patients · ARR-217 was generally well-tolerated · ArriVent to host virtual webinar on Mo

ArriVent BioPharma (AVBP) reported initial Phase 1 results for ARR-217, showing a 44.8% objective response rate at 6 mg/kg dose in pre-treated colorectal cancer patients. The study included 123 patients with gastrointestinal malignancies. ARR-217 is being developed with Lepu Biopharma. Phase 1b dose optimization is underway, with further data expected in 2027.

ArriVent BioPharma (AVBP) advanced its CDH17-targeted ADC, ARR-217, to Phase 1b after initial Phase 1 data in GI cancers. The company expects dose optimization data in 2027. According to the company, the Phase 1b trial will focus on 5–6 mg/kg Q3W dosing.